Graham CN, Davis KL, Goyal RK. Effect of sample size and data maturity on parametric survival modeling projections in advanced cancer. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.
Graham CN, Hechmati G, Hjelmgren J, de Liege F, Knoof A, Lanier J, Knox HN, Barber B, de Pouvourville G. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type ras metastatic colorectal cancer. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.
Graham CN, Hechmati G, Hjelmgren J, de Liege F, Lanier J, Knox H, Barber B. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Nov;50(16):2791-801. doi: 10.1016/j.ejca.2014.08.016
Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
Graham CN, Knox HN, Winfree KB, Hess LM, Liu J, Ortuzar WF. Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC). Poster presented at the Quality Care Symposium of the American Society of Clinical Oncology; November 2013.